Stuart A Arbuckle Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Stuart A Arbuckle is EVP, COO of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 63,368 shares of VRTX, which is worth approximately $29.9 Million. The most recent transaction as insider was on Feb 24, 2023, when has been sold 4,714 shares (Common Stock) at a price of $289.12 per share, resulting in proceeds of $1,362,911. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 63.4K

0.69% 3M change

27.52% 12M change

Total Value Held $29.9 Million

Stuart A Arbuckle Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 24 2023	SELL Payment of exercise price or tax liability	$1,362,911 $289.12 p/Share	4,714 Reduced 7.11%	61,590 Common Stock
Feb 22 2023	SELL Open market or private sale	$706,230 $294.14 p/Share	2,401 Reduced 3.49%	66,304 Common Stock
Feb 21 2023	SELL Open market or private sale	$703,834 $293.02 p/Share	2,402 Reduced 3.38%	68,705 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$1,317,239 $292.85 p/Share	4,498 Reduced 5.95%	71,107 Common Stock
Feb 14 2023	SELL Open market or private sale	$1,909,739 $298.49 p/Share	6,398 Reduced 7.8%	75,605 Common Stock
Feb 13 2023	SELL Open market or private sale	$1,459,062 $298.56 p/Share	4,887 Reduced 5.62%	82,003 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$1,786,577 $298.26 p/Share	5,990 Reduced 6.45%	86,890 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$992,480 $294.33 p/Share	3,372 Reduced 3.5%	92,880 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	38,221 Added 28.42%	96,252 Common Stock
Dec 06 2022	BUY Grant, award, or other acquisition	-	12,753 Added 18.02%	58,031 Common Stock
Aug 15 2022	SELL Open market or private sale	$6,719,527 $303.05 p/Share	22,173 Reduced 32.87%	45,278 Common Stock
Aug 15 2022	BUY Exercise of conversion of derivative security	$1,022,251 $155.57 p/Share	6,571 Added 8.88%	67,451 Common Stock
Aug 10 2022	SELL Open market or private sale	$54,211 $301.17 p/Share	180 Reduced 0.29%	60,880 Common Stock
Aug 10 2022	BUY Exercise of conversion of derivative security	$9,956 $155.57 p/Share	64 Added 0.1%	61,060 Common Stock
Aug 09 2022	SELL Open market or private sale	$1,712,576 $300.98 p/Share	5,690 Reduced 8.53%	60,996 Common Stock
Aug 09 2022	BUY Exercise of conversion of derivative security	$299,628 $155.57 p/Share	1,926 Added 2.81%	66,686 Common Stock
May 16 2022	SELL Open market or private sale	$33,299 $250.37 p/Share	133 Reduced 0.2%	64,760 Common Stock
May 02 2022	SELL Open market or private sale	$80,778 $263.98 p/Share	306 Reduced 0.47%	64,760 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$1,651,074 $227.86 p/Share	7,246 Reduced 10.02%	65,066 Common Stock
Feb 17 2022	SELL Payment of exercise price or tax liability	$959,336 $232.51 p/Share	4,126 Reduced 5.4%	72,312 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$722,730 $237.74 p/Share	3,040 Reduced 3.82%	76,438 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	38,375 Added 32.56%	79,478 Common Stock
Nov 15 2021	SELL Open market or private sale	$562 $187.4 p/Share	3 Reduced 0.01%	41,103 Common Stock
May 17 2021	SELL Open market or private sale	$23,575 $216.28 p/Share	109 Reduced 0.26%	41,103 Common Stock
Feb 25 2021	SELL Open market or private sale	$777,676 $214.0 p/Share	3,634 Reduced 8.12%	41,103 Common Stock

Also insider at

RYTM

RHYTHM PHARMACEUTICALS, INC. Healthcare

Director

IMGN

ImmunoGen, Inc. Healthcare

Director

SAA